What is Unity Biotechnology's (UBT) price potential for the next year?
Their forecasts range from $5.00 to $12.00. On average, they anticipate Unity Biotechnology's stock price to reach $7.67 in the next year. This suggests a possible upside of 129.5% from the stock's current price.
Where can I buy shares of Ubx?
Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is UBX a sell or buy on Robinhood?
Today UBX ranks #16251 as sell candidate. Get a Free Stock at Robinhood Which way will UBX go? * StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
Is Ubx a good stock to buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: UBX) stock is to Strong Buy UBX stock.
Why is Ubx stock dropping?
Why Did Unity Biotechnology Stock Fall? The reason for Unity's stock value falling is directly tied to the results of its second-phase clinical results for UBX0101. The drug is meant to treat moderate to severe osteoarthritis (OA) in the knee.
What is the forecast for Ubx stock?
Stock Price Forecast The 6 analysts offering 12-month price forecasts for UNITY Biotechnology Inc have a median target of 6.00, with a high estimate of 12.00 and a low estimate of 3.00. The median estimate represents a +753.12% increase from the last price of 0.70.
Who bought Ubx stock?
GSA Capital Partners LLPInstitutional investors purchased a net $846.6 thousand shares of UBX during the quarter ended June 2019....Top 10 Owners of UNITY Biotechnology Inc.StockholderGSA Capital Partners LLPShares owned724,202Total value ($)407,726Shares bought / sold+28,0879 more columns
What biotech company is working on zombie cells?
Oisín raises $5M to develop treatments for 'zombie cells' associated with age-related diseases. New funding: Seattle biotech startup Oisín Biotechnologies has raised a $5 million seed round.
What happened to unity biotechnology?
Unity Biotechnology shares dropped 60% on August 17, 2020, after the company reported disappointing results from a clinical trial involving its lead drug candidate, UBX0101, in patients with moderate-to-severe painful osteoarthritis.
How do I buy biotechnology stock in unity?
How to buy shares in Unity BiotechnologyCompare share trading platforms. Use our comparison table to help you find a platform that fits you.Open your brokerage account. Complete an application with your details.Confirm your payment details. ... Research the stock. ... Purchase now or later. ... Check in on your investment.
Who are the major investors in unity biotechnology?
Largest shareholders include Fmr Llc, Pura Vida Investments, Llc, Vanguard Group Inc, FDGRX - Fidelity Growth Company Fund, Renaissance Technologies Llc, Pura Vida Investments, Llc, Millennium Management Llc, Caption Management, LLC, Gsa Capital Partners Llp, and Marshall Wace, Llp.
Should I buy or sell Unity Biotechnology stock right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are...
What is Unity Biotechnology's stock price forecast for 2022?
4 analysts have issued 1-year price targets for Unity Biotechnology's shares. Their forecasts range from $4.00 to $12.00. On average, they predict...
How has Unity Biotechnology's stock price performed in 2022?
Unity Biotechnology's stock was trading at $1.46 at the start of the year. Since then, UBX stock has decreased by 53.4% and is now trading at $0.67...
When is Unity Biotechnology's next earnings date?
Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for U...
How were Unity Biotechnology's earnings last quarter?
Unity Biotechnology, Inc. (NASDAQ:UBX) announced its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.28) EPS for the quarte...
Who are Unity Biotechnology's key executives?
Unity Biotechnology's management team includes the following people: Dr. Anirvan Ghosh Ph.D. , CEO & Director (Age 58, Pay $885.54k) Dr. Nathani...
Who are some of Unity Biotechnology's key competitors?
Some companies that are related to Unity Biotechnology include Agronomics (ANIC) , Theratechnologies (THERF) , Viemed Healthcare (VMD) , Select...
What other stocks do shareholders of Unity Biotechnology own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO) , Ins...
When did Unity Biotechnology IPO?
(UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sa...
What is Ubx1325?
How long does it take for UBX1325 to work?
UBX1325 is currently being evaluated in clinical trials for the treatment of age-related diseases of the eye, including diabetic macular edema, diabetic retinopathy and age-related macular degeneration. About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging.
What is unity biotechnology?
Evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks Sustained responses following single treatment with UBX1325 support durability of senolytic therapeutic approach; data builds on previously reported results at 8 weeks Study remains on track with 24-week data expected before the end of the year UNITY to host investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., on October 5, 2021 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif.,
How much cash was used in operations in 2021?
(“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will participate in the following upcoming March virtual investor conferences: Cowen 41st Annual Healthcare Conference Date: March 3, 2021Presentation Time: 1:20 p.m. ET 33rd Annual ROTH ConferenceDate: March 15, 2021Presentation Time: 4:00 p.m. ET A live audio webcast of the presentations will be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following each event. About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn. CONTACT: Investors Gilmartin Group Matt Lane [email protected] Media Canale Communications Jason Spark [email protected]
Who is the general counsel of Unity Biotechnology?
Cash used in operations during the first quarter of 2021 was $15.1 million compared to $25.1 million for the first quarter of 2020. Research and development expenses decreased by $10.6 million, to $8.7 million for the three months ended March 31, 2021, from $19.3 million for the three months ended March 31, 2020.
Is Ubx1325 safe?
(“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has been appointed general counsel. “Alex brings extensive operational and regulatory experience in the life sciences industry that will help him build our company’s legal function,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “He is a dynamic leader with deep roots in the fields of business, government and law. I am pleased to welcome him to our team and believe his expertise will serve us well as we continue to advance our clinical pipeline in ophthalmology and other age-related diseases.” Mr. Nguyen previously worked for three Roivant Sciences companies where he served as general counsel at Alyvant, head of legal at Axovant, and as head of compliance at Roivant Sciences. His responsibilities included all corporate legal work, SEC filings, equity financings, venture debt deals, licensing agreements, corporate governance at board meetings, litigation, internal investigations, asset recovery, HR, IT, compliance, and risk management. He also led the drafting and negotiation of term sheets and oversaw due diligence for acquisition of commercial-stage assets. Before that, he handled a wide range of high-stakes litigation and investigations in the private as well as the public sector, including as deputy section chief and federal prosecutor at the U.S. Attorney’s Offices in Alexandria and Philadelphia, respectively, successfully leading dozens of cases involving cybercrime, data breaches, IP and trade secrets violations, FDA regulatory offenses, illegal importation of adulterated and misbranded pharmaceuticals, prescription drug diversion, white collar crime, identity theft and tax violations. Mr. Nguyen also served as assistant White House counsel, managing and implementing key White House policy initiatives across Cabinet and federal agencies. He obtained his undergraduate degree from Harvard University and his law degree from Yale Law School. About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn. CONTACT: Investors Gilmartin Group Matt Lane [email protected] Media Canale Communications Jason Spark [email protected]
What is UBX1967?
UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD) Results from Phase 1 study of UBX1325 in additional patients with wet AMD expected by end of year UBX1325 Phase 2a proof-of-concept study enrolling patients with DME; data expected first half of 2022 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) --
What is Unity Biotechnology?
It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
Where is Unity Biotechnology located?
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
What is Unity Biotechnology?
Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Is Ubx1325 a BCL inhibitor?
Unity Biotechnology is developing a drug pipeline based on the idea that clearing senescent cells, or cells that stop dividing, can help to treat or reverse age-related diseases. It's possible that a mechanism to finely control senescent cell populations related to age-related diseases -- while sparing health-related cell populations -- will be discovered and commercialized, but there are simply too many unknowns for investors to confidently bet on any pipeline or technology.
Do hedge funds have to report at the end of every quarter?
UBX1325 is a small molecule inhibitor of Bcl-xL and was well-tolerated with no treatment-related adverse events or dose-limiting toxicities. Additionally, the majority of DME and wet AMD patients treated with a single injection of U. Insider Monkey • last month.
Is Unity Biotechnology, Inc. (NASDAQ:UBX) Popular Amongst Institutions?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F ]
What is Unity Biotechnology?
Every investor in Unity Biotechnology, Inc. ( NASDAQ:UBX ) should be aware of the most powerful shareholder groups...
Does market cap include convertible securities?
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases and pulmonary diseases.
What is Mizuho's price target for 2021?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Is Unity Biotechnology Inc. stock A Buy?
On Nov 09, 2021 "Mizuho" gave "" rating for UBX. The price target was set to $2.57+8.9% .
How many X is Zacks?
Unity Biotechnology Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.
What is unity biotechnology?
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
How many sectors are there in Zacks?
UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States.
What are the different grades for stocks?
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
Is ZacksTrade a separate company?
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
